Agios Pharmaceuticals Announces Investor Conference Schedule
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a trailblazer in cellular metabolism and PK activation, is set to make a significant impact at upcoming investor conferences. The company specializes in pioneering therapies for rare diseases, and their management team is gearing up to engage with investors and healthcare professionals alike.
Conference Highlights
This March, Agios will participate in two major conferences designed to showcase their advancements and ongoing initiatives:
- Leerink Global Healthcare Conference 2025: A fireside chat is scheduled for Tuesday, March 11, at 10:50 a.m. ET.
- Barclays 27th Annual Global Healthcare Conference: Another fireside chat will take place on Wednesday, March 12, at 12:30 p.m. ET.
Investors can look forward to live webcasts of these events, which will be available in the Investors section on Agios' official website. The company will ensure that these presentations are accessible, with replays available for two weeks following the events.
Transformative Therapies from Agios
At the heart of Agios' mission is its commitment to developing and delivering transformative therapies for patients living with rare diseases. They proudly market a first-in-class pyruvate kinase (PK) activator specifically for adults suffering from PK deficiency. This innovative treatment is noted for being the first disease-modifying therapy for a rare and chronic form of hemolytic anemia.
Leading the Charge Against Rare Diseases
Agios leverages its extensive expertise in classical hematology combined with a strong focus on cellular metabolism and rare hematologic disorders. The company is currently advancing a clinical pipeline that includes potential treatments for various conditions such as:
- Alpha- and beta-thalassemia
- Sickle cell disease
- Pediatric PK deficiency
- Myelodysplastic syndromes (MDS)-associated anemia
- Phenylketonuria (PKU)
In addition to these clinical trials, Agios is excited about the progress of a preclinical TMPRSS6 siRNA treatment that could potentially address polycythemia vera.
Focus on Investor Outreach
Agios understands the importance of keeping open lines of communication with investors and stakeholders. The participation in these conferences reflects their commitment to transparency and engagement with the investment community.
Contact Information for Inquiries
For investor inquiries, Agios Pharmaceuticals has provided contact details for their Investor Relations team:
Investor Contact:
Chris Taylor, Vice President, Investor Relations and Corporate Communications
Agios Pharmaceuticals
Email: IR@agios.com
For media inquiries, please reach out to:
Media Contact:
Eamonn Nolan, Senior Director, Corporate Communications
Email: Media@agios.com
Frequently Asked Questions
1. What is Agios Pharmaceuticals focused on?
Agios Pharmaceuticals is focused on developing transformative therapies for patients with rare diseases, particularly in the field of cellular metabolism.
2. When will Agios present at the upcoming conferences?
Agios will present at the Leerink Global Healthcare Conference on March 11 and the Barclays Global Healthcare Conference on March 12.
3. Where can I access the conference webcasts?
The webcasts will be accessible on the Investors section of Agios' official website, available for two weeks post-event.
4. Who can I contact for more information about Agios?
For investor inquiries, Chris Taylor can be contacted through his email, and for media inquiries, Eamonn Nolan is available.
5. What treatments is Agios developing?
Agios is developing treatments for conditions such as PK deficiency, thalassemia, sickle cell disease, and PKU, among others.
